Breathing Simulation Testing

Inhalation Science

Programmable breathing simulators support adult and pediatric mouth/nose fixtures. Dose is collected with cascade impactors or filters and quantified by HPLC, ELISA, or ddPCR, depending on the study.

Purpose & when to use

Breathing Simulation Testing uses a programmable pump to reproduce human inhalation profiles, including tidal volume, flow rate, and breath duration. ARE Labs then quantifies the inhaled and respirable dose delivered through the device interface. Compendial configurations align with USP <601> and USP <1601>, while adult and pediatric profiles can be programmed within the framework of ISO 27427 and FDA guidance for MDI, DPI, and nasal products. Breathing simulation is used for:

Inhaled dose comparisons across MDIs, DPIs, nebulizers, and soft-mist inhalers — profile-resolved dose datasets aligned to USP <601> and FDA MDI / DPI / nasal guidance for submission and change-control packages.
Pediatric-to-adult profile mapping for inhalation and intranasal products — bracketing use-condition variability across age-scaled tidal volumes and flow rates under FDA pediatric-study guidance.
Mask and valved holding chamber (VHC) interface-effect studies — quantifying leakage, dead-space, and coordination impacts under ISO 27427 nebulizing-equipment and FDA MDI / DPI guidance framing.
Respirable-fraction estimation by pairing breathing simulation with [cascade impactor PSD](/testing-services/particle-aerosol-measurement/psd-testing/) — links device emissions to predicted lung deposition under USP <601> aerodynamic-size framing.
Sensitivity and profile-variability mapping across breathing conditions, actuation timing, and device orientation — supports ICH Q9 risk-assessment and FDA change-control packages.

Breathing simulation is appropriate when inhaled-dose data must reflect realistic use conditions, including pediatric or adult profiles, interface variability, or comparisons across devices. The resulting dataset can support engineering decisions, regulatory submissions, or risk-assessment packages.

Built for inhalation and intranasal drug delivery devices

Breathing simulation characterises performance across the device classes where realistic use conditions — patient breathing pattern, interface geometry, and actuation timing — drive the dose the patient receives.

MDIMetered-dose inhalers
DPIDry-powder inhalers
NebulizerLiquid aerosol generators
Nasal sprayIntranasal pump delivery
Spacer / VHCValved holding chambers

Instrumentation & measurement ranges

ARE Labs selects the platform based on the device class, breathing profile, and regulatory framework. Study components are confirmed during planning and documented in the method report.

5 – 100 L/mininhalation-flow

Programmable breathing simulator (ASL 5000 or equivalent)

Piston-driven breathing pump with programmable tidal volume, flow rate, and breath duration — adult and pediatric profiles selectable; profile fidelity verified against the set waveform before each campaign.

0.1 – 5 sinhalation-duration

Adult and pediatric mouth/nose fixtures and headforms

USP-geometry induction ports, adult/pediatric nose-throat models, and headform-style interfaces — geometry matched to the device class and the patient population under study.

0.4 – 11 µmaerodynamic

Cascade impactors and filter-based collection (NGI / Andersen)

Downstream dose collection via NGI or Andersen cascade impactor stages, or a validated filter assembly — collection method selected to match the size-fraction and dose endpoint required.

0.1 – 1000 µgper-profile

Analytical quantitation suite (HPLC, ELISA, qPCR / ddPCR)

HPLC for small-molecule actives, ELISA for protein analytes, and qPCR / ddPCR for nucleic-acid actives — assay matched to the active and matrix, with system suitability and recovery documented per assay.

Test method options

Method	Strengths	Tradeoff	Aligned with
Compendial-aligned breathing simulation (USP <601> / <1601>)	Submission-grade inhaled-dose datasets under defined fixtures and breathing profiles — the canonical USP <601> and USP <1601> compendial package for inhalation characterisation. Documented acceptance logic and statistical framing for FDA MDI / DPI / nasal submissions, lifecycle changes, and predicate comparisons.	Strict configuration control and documentation overhead — best when device and formulation are locked enough to justify the filing-bound setup cost.	USP <601>USP <1601>FDA MDI / DPI / nasal
Interface and mask effects study (fixture sweep)	Directly measures mask, spacer, and VHC leakage effects on inhaled dose — answers the interface-sensitivity question FDA MDI / DPI guidance requires. Controlled fixture protocol surfaces dose differences attributable to interface geometry alone, isolating interface impact from device variability.	Careful fixture fabrication and leak-check protocol needed to avoid measurement artifacts that obscure real interface effects.	FDA MDI / DPI / nasalISO 27427
User-variability mapping (breathing profile sweep)	Brackets realistic breathing-pattern variability from pediatric low-flow to adult high-flow profiles — supports ICH Q9 risk-assessment and FDA change-control packages. Profile-resolved dose dataset directly informs device-label guidance (optimal flow rate, coordination requirements) and user-group selection rationale.	More profiles increase replicate count and study duration — scope tightly to the profile range that drives the specific decision.	ICH Q9FDA MDI / DPI / nasal
Emissions-to-exposure translation (fit for purpose)	Links device emissions to breathing-zone inhaled dose under defined scenarios — supports exposure assessment beyond the compendial collection endpoint. Pairs with emitted-dose data to build a full dose-to-patient picture; framing aligned to FDA CMC guidance for consumer and medical devices.	Requires explicit scenario definition and documented assumptions — results are scenario-specific and must be scoped carefully to avoid over-generalisation.	FDA MDI / DPI / nasal

Setup configurations

Each breathing simulation study uses a configuration matched to the device, patient population, and regulatory framework. The setup must reproduce the required tidal volume, flow rate, and breath duration while accommodating the practical requirements of the collection train and quantitation method. The dimensions below are confirmed during study planning:

Device interfaces

Mouthpiece adapters, USP induction ports, adult/pediatric nose-throat models, and headform interfaces — geometry matched to the device class and the target patient population.

Flow & actuation profiles

Programmable tidal volume, peak flow rate, and inhalation duration — adult and pediatric waveforms logged against the set profile before each campaign with actuation timing synchronised to breath phase.

Sample numbers

Replicates per device and per profile — power sized to declared within-profile and device-to-device variability with documented statistical framing.

Media & handling

Collection-media selection (filter or impactor stages), extraction-solvent compatibility, and documented storage and chain of custody for collected fractions.

Environmental controls

Temperature and humidity conditioning when formulation or device performance is known to be sensitive — equilibration and environmental monitoring logged alongside dose collection.

Compliance frame for inhalation breathing simulation

Each breathing simulation study is conducted within a documented quality system tied to the pharmacopoeial and regulatory frameworks for inhalation and intranasal products. The four anchors below define the data requirements carried through the Section 7 outputs.

ISO 17025AccreditedTesting-laboratory competence — documented methods, calibration traceability, and uncertainty contributors.
USP <601>AccreditedInhalation and nasal drug products — performance quality tests with breathing-simulation provisions.
USP <1601>AlignedProducts for nebulization — characterization tests including breathing-simulator methods.
FDA MDI / DPI / nasalAlignedChemistry, manufacturing, and controls plus breathing-pattern testing for inhalation submissions.

Key data outputs & reporting

Each breathing simulation study provides inhaled-dose results by profile and condition, repeatability statistics, and the underlying datasets. Results are formatted for submission packages, change-control documentation, or engineering decisions. Primary deliverables include profile-resolved dose data, interface-sensitivity comparisons, and respirable-fraction context. Traceable QA / QC records, including profile verification logs, fixture leak checks, and assay calibration records, are maintained throughout the study and included with the final report.

Primary outputs

Inhaled and respirable dose by breathing profile and condition — mean, SD, and CV across replicates, with profile-to-profile comparisons.
Interface sensitivity data — dose delta attributable to mask, spacer, or VHC geometry, with documented fixture-leak controls.
Assay calibration, recovery, and uncertainty contributors documented alongside results for inspection-readiness.

Deliverables

#	Format	Contents
01	PDF report	Methods, breathing-profile setup, controls, statistical framing, and acceptance logic.
02	CSV / XLSX datasets	Per-profile inhaled dose, replicate statistics, and condition deltas.
03	Figures	Dose-versus-profile plots, condition overlays, and interface-sensitivity charts for internal review and submission appendices.

QA / QC & data integrity

Each breathing simulation study includes a documented QA / QC program matched to the method plan. Controls and verification steps reflect the required profile fidelity, collection train, and analytical method. These checks run alongside dose collection, are audited under our ISO 17025 quality system, and remain traceable from sample receipt through the final result.

Profile verification logs — breathing-simulator waveform confirmed against the set tidal volume, flow rate, and duration before each campaign and between condition blocks.

Fixture leak checks before and after each collection series — documented to bound leakage contribution to dose uncertainty.

Blanks and background controls for collection media, with stage and filter blanks run alongside device measurements.

Assay controls — calibration standards, system suitability per assay, and spike-recovery on matrix-challenging analytes across HPLC, ELISA, and ddPCR endpoints.

Chain of custody from sample receipt through collection, extraction, quantitation, and final reporting.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)

17025Accredited testing

900+Studies Performed

17+Years in operation

300+Clients supported

Common questions

These answers address common questions from inhalation and intranasal product teams about breathing profile selection, pediatric testing, interface effects, quantitation, and deliverables. They are intended as starting points. Most breathing simulation studies require at least one custom configuration decision, so contact ARE Labs if your device class, patient population, or regulatory framework differs from the examples below.

Q.Can you run pediatric and adult breathing profiles in the same study?

A.Yes. We can program adult and pediatric profiles within the same campaign and report dose metrics for each profile. This allows one physical device campaign to produce an age-bracketed dataset for use in pediatric regulatory submissions.

Q.How do you measure inhaled dose from the breathing simulator?

A.Dose is collected downstream of the mouth/nose interface using a filter or cascade impactor. ARE Labs then quantifies the active by HPLC, ELISA, or ddPCR, depending on the active and matrix. Assay controls, blanks, and recovery are documented.

Q.Can you evaluate mask and spacer interface effects?

A.Yes. Mask and VHC effects are common study objectives. ARE Labs runs controlled fixture sweeps with documented leak checks, then reports the dose difference associated with interface geometry while controlling device variability.

Q.Is breathing simulation only for pharmaceutical products?

A.No. Breathing simulation can also quantify inhaled dose from consumer and medical devices when realistic breathing conditions affect the exposure assessment. The same simulator and collection methodology are used, with the study framed around the relevant regulatory or engineering decision.

Q.What do I receive at the end of the study?

A.Deliverables include a PDF report documenting setup assumptions, profile logs, controls, and statistical framing; CSV / XLSX datasets containing dose results and replicate statistics for each profile; and figures comparing dose across profiles and test conditions.

Standards & guidance

ARE Labs aligns breathing simulation studies with the pharmacopoeial, consensus, and regulatory standards that govern inhaler characterisation and inhalation product submissions. Methods within our third-party accredited scope are identified as accredited, including applicable ISO 17025 and USP <601> methods. When a standard is followed outside that accredited scope, the method is described as aligned or conformant, where applicable. The cards below identify the standards most often used in breathing simulation packages.

Inhalation & Drug Delivery - Accredited

Related services & devices

Service